Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06354218
Status:
RECRUITING
Last Update Posted:
2024-04-09
First Post:
2024-04-03
Brief Title:
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
A Single Arm Prospective Exploratory Single Center Phase II Clinical Study of Serplulimab Combined With Synchronous Radiochemotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Cancer in Elderly Patients With Non Surgical Resectable Lesions Research Plan
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a Single Arm Prospective Exploratory Single Center Phase II Clinical Study to evaluate the effectiveness of the combination of Serplulimab and Concurrent Chemoradiotherapy in the treatment of elderly patients with locally advanced esophageal cancer who cannot be treated surgicallySubjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria
Detailed Description:
It is expected that 50 patients will be enrolled and patients who meet the enrollment criteria will undergo esophagoscopy esophageal barium meal examination chest contrast-enhanced CT abdominal ultrasound electrocardiogram blood routine whole body bone scan liver and kidney function and other examinations before treatment and esophageal ultrasound if necessary Patients who received esophageal ultrasound were staged by esophageal ultrasound results and those without esophageal ultrasound were mainly staged according to the cervical chest and epigastric contrast CT and esophageal barium plates and clinical staging was performed according to the AJCC staging standard After the combination of Serplulimab and concurrent chemoradiotherapy adverse reactions and efficacy evaluation were observed The expected result is that the local control rate of Serplulimab combined with chemoradiotherapy is improved in patients with locally advanced elderly esophageal squamous cell carcinoma and there is no significant increase in adverse reactions and serological indicators such as PDL-1 CPS can be used as prognostic indicators for esophageal malignancy and have certain guiding significance for treatment PD-1 monoclonal antibody can be used in locally advanced elderly esophageal cancer patients who cannot tolerate chemotherapy with good short-term efficacy and tolerable toxic side effects which further provides reference value for clinical guidance
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None